Dexrazoxane

Published

dm+d

417741009

Articles

Safety in Lactation: Drugs for cytotoxic-induced side-effects

25 September 2020As these drugs are used to prevent, or treat, specific adverse effects of certain antineoplastic agents or radiotherapy, the risk of their use in breastfeeding…
Search Articles

Lactation Safety Information

No published evidence of safety
Used to protect against cardiotoxicity of doxorubicin/ epirubicin anthracyclines
Short half-life (2-2.5 hours), and suspension of breastfeeding during associated chemotherapy, would eliminate risk from dexrazoxane if breastfeeding resumed (see summary)
Monitor infant for possible signs of myelosuppression
21 September 2020